Vitaly Margulis, MD, highlights the phase 3 ENLIGHTED trial

At the 2025 Society of Urology Oncology Annual Meeting in Phoenix, Arizona, Vitaly Margulis, MD, sat down with Urology Times® to discuss the phase 3 ENLIGHTED trial (NCT04620239), which is evaluating the safety and efficacy of padeliporfin vascular targeted photodynamic therapy for patients with low-grade upper tract urothelial carcinoma.¹

Margulis is a urologic oncologist at UT Southwestern Medical Center in Dallas, Texas.

REFERENCE

1. Margulis V. ENLIGHTED Phase 3 study: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment ofLow-grade Upper Tract Urothelial Cancer (LG UTUC). Presented at: Society of Urologic Oncology Annual Meeting; December 2-5, 2025; Phoenix, Arizona. Abstract 166. https://suo-abstracts.secure-platform.com/a/gallery/rounds/24/details/4472